Moniyot-131 (Sodium Iodide (131i))

Sodium Iodide I-131, the active ingredient in Moniyot-131, is a radiopharmaceutical presented as a oral solution for oral use. It treats hyperthyroidism, thyroid cancer and post‑surgical thyroid ablation by selectively destroying thyroid tissue. GNH USA supplies Moniyot-131 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Moniyot-131 is used in thyroid‑targeted therapy to manage conditions that involve excess or malignant thyroid tissue.

Hyperthyroidism: reduces hormone production by ablating overactive thyroid cells. Thyroid cancer: destroys residual cancer cells after surgery. Post‑surgical thyroid ablation: eliminates remaining thyroid tissue to facilitate further radioactive iodine treatment.

Adverse reactions to Moniyot-131 may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Salivary gland swelling: transient enlargement and tenderness. - Dry mouth: reduced salivary flow. - Taste alteration: temporary metallic taste.

Serious or Rare Side Effects: - Bone marrow suppression: decreased blood cell counts, increasing infection or bleeding risk. - Radiation thyroiditis: painful inflammation of thyroid tissue. - Pulmonary fibrosis: rare lung scarring after high cumulative doses.

Moniyot-131 requires careful consideration of several safety factors. - Pregnancy: contraindicated; category X due to fetal radiation exposure. - Breastfeeding: not recommended; iodine may be secreted in milk. - Thyroid function testing: perform baseline and periodic assessments. - Antithyroid medications: discontinue before administration to avoid reduced uptake. - Renal impairment: evaluate iodine clearance and adjust monitoring. - Store at ambient temperature: keep below 25°C, protect from moisture and light in the original container.

Moniyot-131 may interact with other medicines that affect iodine uptake or clearance.

Major Interactions (Avoid): - Lithium: reduces radioactive iodine uptake, diminishing efficacy. - Amiodarone: high iodine content interferes with treatment outcomes. - Antithyroid drugs (methimazole, propylthiouracil): block iodine uptake; should be stopped prior.

Moderate Interactions (Monitor Closely): - Calcium supplements: may decrease absorption if taken simultaneously. - Iron preparations: can reduce iodine uptake; separate dosing by several hours. - Diuretics (thiazides): may alter renal clearance of iodine.